Preclinical investigations have shown that these agents downregulate proprotein convertase subtilisin/kexin type 9 (PCSK9) expression, upregulate low-density lipoprotein receptor (LDLR) levels, and suppress postprandial secretion of triglycerides and chylomicrons (87, 88)
This has led to concerns over the sources of compounded semaglutide and the use of different formulations, such as semaglutide sodium
PubMed laboratory research record [PMID: 42278967] PubMed record related to this compound for laboratory literature review
Side effects like constipation , burping , dizziness , and fatigue can occur even when the medication looks perfectly normal
Do not use if you have any medical condition, are taking medication, or are under 21 years old
National Multiple Sclerosis Society